- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Basilea Pharmaceutica
Add to PortfolioBSLN:SW
42.00 CHF 0.10 0.24%As of 11:31:31 ET on 05/25/2012.
Snapshot for Basilea Pharmaceutica (BSLN)
| Open: | 42.65 | Day's Range: | 41.60 - 42.70 | Volume: | 20,509 | Bid: | 42.00 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 42.10 | 52wk Range: | 28.55 - 73.25 | 1-Yr Rtn: | -40.51% | Ask: | 42.25 |
Key Statistics for BSLN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (CHF) (ttm) | -6.0100 |
| Est. EPS (CHF) (12/2012) | -7.5140 |
| Est. PEG Ratio | - |
| Market Cap (M CHF) | 402.68 |
| Shares Outstanding (M) | 9.59 |
| Enterprise Value (M CHF) (ttm) | 205.53 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 2.6273 |
| Price/Sale (ttm) | 6.0370 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/16/2012 |
More BSLN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for BSLN
- Operating
- Investing
- Financing (M/CHF)
Company Profile & Key Executives for BSLN
Basilea Pharmaceutica AG is a biotechnology company conducting research into the development of drugs for the treatment of infectious diseases and dermatological problems. The Company develops anti-bacterial and anti-fungal compounds which destroy infectious organisms.
| Werner HenrichChairman | Hans Beat GuertlerVice Chairman |
| Anthony ManChief Executive Officer | Ronald Scott "Ron"Chief Operating Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page